期刊
PHARMACEUTICALS
卷 13, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/ph13120418
关键词
CDK6; MAPK; p38; combinational; palbociclib; inhibitors; cancer
资金
- European Research Council (ERC) under the European Union [694354]
- University of Veterinary Medicine Vienna
- European Research Council (ERC) [694354] Funding Source: European Research Council (ERC)
Despite the development of targeted therapies and novel inhibitors, cancer remains an undefeated disease. Resistance mechanisms arise quickly and alternative treatment options are urgently required, which may be partially met by drug combinations. Protein kinases as signaling switchboards are frequently deregulated in cancer and signify vulnerable nodes and potential therapeutic targets. We here focus on the cell cycle kinase CDK6 and on the MAPK pathway and on their interplay. We also provide an overview on clinical studies examining the effects of combinational treatments currently explored for several cancer types.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据